Registration for a live webinar on 'Innate immunity, inflammation and cancer' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
23 min
1. Coronary heart disease epidemiology: global context for a new genetic understanding- Prof. Harry Hemingway
-
44 min
2. Cardiovascular risk factors- Dr. Michal Vrablik
-
29 min
3. Lipid metabolism- Dr. Ulrike Beisiegel
-
39 min
4. Thrombotic risk factors for cardiovascular disease- Prof. Gordon Lowe
- Biology of Coronary Heart Disease
-
42 min
5. Plaque rupture- Prof. Petri Kovanen
-
56 min
6. Transcription factors and complex disease development- Dr. Ines Pineda-Torra
-
39 min
7. Animal models to explore cardiovascular disease- Prof. Martin Merkel
- Treatment
-
26 min
8. Diagnosis and treatment of dyslipidemias- Prof. Anton Stalenhoef
-
31 min
9. Key drug discovery challenges in cardiovascular medicine- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
50 min
10. Moving from GWAS hits to functional variants- Prof. Steve Humphries
-
51 min
11. Heart disease genes and SNPs- Prof. Steve Humphries
-
39 min
12. Familial hypercholesterolaemia: genetic causes and treatment- Prof. Steve Humphries
-
22 min
13. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes- Prof. Steve Humphries
-
28 min
-
52 min
15. Genetics of cardiovascular disease- Prof. Philippa Talmud
-
35 min
-
33 min
17. The genetics of abdominal aortic aneurysm- Dr. Seamus Harrison
-
49 min
18. Genome scans for hypertension- Prof. Patricia Munroe
-
43 min
19. Telomeres and cardiovascular disease- Dr. Jess Buxton
-
33 min
- Archived Lectures *These may not cover the latest advances in the field
-
44 min
21. Gene-environment interaction and oxidative stress in cardiovascular disease- Dr. Jeffrey Stephens
-
34 min
22. Gene therapy as a therapeutic option for lipoprotein lipase deficiency- Dr. Jan Albert Kuivenhoven
-
60 min
23. Cardiovascular diseases: from epidemiology to nutritional interventions- Dr. Antonis Zampelas
-
45 min
24. Genetic testing for CHD risk: fact or fiction?- Prof. Steve Humphries
-
35 min
25. Pharmacogenetics: progress, pitfalls and clinical potential- Prof. Steve Humphries
-
50 min
26. Familial hyperchlolesterolaemia: a monogenic cause of early CHD- Prof. Steve Humphries
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Pharmacogenetics: vision of the future?
- Pharmacogenetics and clinical potential
- Major potential areas of patient benefit
- Treatment of high blood cholesterol by statins
- Pharmacogenetics of statin response (1)
- Pharmacogenetics of statin response (2)
- Better-than-average response: LDL plasma levels
- Better-than-average response: inflammation
- WOSCOPS study
- Pharmacogenetics - IL6 genotype and CHD risk
- Better-than-average response: conclusions
- Pharmacogenetics - pitfalls
- The REGRESS trial and CETP genotype (1)
- The REGRESS trial and CETP genotype (2)
- CETP TaqI meta-analysis
- CETP TaqI - pravastatin meta-analysis
- Use of pharmacogenetics to avoid side-effects
- Warfarin, CYP2C9*3 and avoiding bleeds
- The TPT trial and bleeds by CYP2C9 genotype
- Ethical concerns: pharmacogenetics and ethnicity
- Summary: progress, pitfalls and clinical potential
Topics Covered
- Therapeutic index, genetic variation determining codine and thiopurine metabolism
- Pharmacogenetics and statin response, involvement of HMG co-reductase
- Statin response in patients with FH
- Anti-inflammatory effects of statins and the IL-6 gene
- Pravastatin and CETP genotype
- Initial studies
- Pravastatin and CETP genotype
- Meta-analysis results
- Use of pharmacogenetics to avoid side effects
- Warfarin and CYP2C9 as an example
- Ethical concerns
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Humphries, S. (2008, November 24). Pharmacogenetics: progress, pitfalls and clinical potential [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 20, 2024, from https://hstalks.com/bs/1063/.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Humphries is the Medical Director of StoreGene a UCL spin out company that offers DNA testing for Cardiovascular Disease risk including testing for FH. Professor Humphries is a consultant for Verve Therapeutics, a US based company that is developing gene-editing agents to treat individuals with hypercholesterolaemia, including those with FH.
